<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01213433</url>
  </required_header>
  <id_info>
    <org_study_id>016-2010</org_study_id>
    <nct_id>NCT01213433</nct_id>
  </id_info>
  <brief_title>Amodiaquine+Artesunate for Uncomplicated Malaria Treatment</brief_title>
  <acronym>ASAQ-MAL</acronym>
  <official_title>Amodiaquine+Artesunate for the Treatment of Uncomplicated Falciparum Malaria in Nanoro, Burkina Faso</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Muraz</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Institute of Tropical Medicine, Belgium</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Centre Muraz</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase IV one-arm study aiming at recruiting 50 patients to assess the efficacy of
      AQ+AS in patients with a positive RDT diagnosis of malaria in Nanoro, Burkina Faso.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2010</start_date>
  <completion_date type="Actual">April 2011</completion_date>
  <primary_completion_date type="Actual">November 2010</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Treatment failure at day 28</measure>
    <time_frame>28 days</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">150</enrollment>
  <condition>Uncomplicated Malaria</condition>
  <arm_group>
    <arm_group_label>Amodiaquine+Artesunate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Artesunate-Amodiaquine</intervention_name>
    <description>Coformulated AQ+AS by Sanofi-Aventis has been pre-qualified by WHO in 2008.It is administered once daily for three consecutive days, and it is available in three different dosages (25mg/67.5mg; 50mg/135mg; 100mg/270mg)</description>
    <arm_group_label>Amodiaquine+Artesunate</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Males and Females aged 6 months and above.

          -  Body weight of 5 Kg and above.

          -  RDT positive test.

          -  Fever (axillary temperature at ≥ 37.5°C) or history of fever in the previous 24 hours.

          -  Signed (or thumb-printed whenever patients are illiterate) informed consent.

          -  Patients' willingness and ability to comply with the study protocol for the duration
             of the study.

        Exclusion Criteria:

          -  Participation in any other investigational drug study (antimalarial or others) during
             the previous 30 days.

          -  Known hypersensitivity to the study drugs.

          -  Severe malaria.

          -  Danger signs: not able to drink or breast-feed, vomiting (&gt; twice in 24hours), recent
             history of convulsions (&gt;1 in 24h), unconscious state, unable to sit or stand.

          -  Known intercurrent illness or any condition (cardiac, renal, hepatic diseases) which
             in the judgement of the investigator would place the subject at undue risk or
             interfere with the results of the study.

          -  Severe malnutrition (defined as weight for height &lt;70% of the median NCHS/WHO
             reference).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Months</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>CRUN</name>
      <address>
        <city>Nanoro</city>
        <state>Boulkiemdé</state>
        <zip>01</zip>
        <country>Burkina Faso</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Burkina Faso</country>
  </location_countries>
  <verification_date>July 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 30, 2010</study_first_submitted>
  <study_first_submitted_qc>October 1, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 4, 2010</study_first_posted>
  <last_update_submitted>July 29, 2015</last_update_submitted>
  <last_update_submitted_qc>July 29, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 31, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Centre Muraz</investigator_affiliation>
    <investigator_full_name>Tinto Halidou</investigator_full_name>
    <investigator_title>PharmD, PhD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Malaria</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Artesunate</mesh_term>
    <mesh_term>Artemisinins</mesh_term>
    <mesh_term>Amodiaquine</mesh_term>
    <mesh_term>Amodiaquine, artesunate drug combination</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

